Skip to content

Author

Kenichi Hakamada

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Limited Survival Benefit of Short-Course Neoadjuvant Gemcitabine Plus Nab-Paclitaxel for Resectable Pancreatic Cancer: A Prospective Phase II Study With a Propensity Score-Matched Analysis.

Prolonged preoperative GnP may improve outcomes, suggesting that treatment duration may be a key determinant of efficacy, and survival comparable to historical controls treated with upfront surgery is demonstrated.

K. Ishido, N. Kimura, H. Nagase et al. · 0 citations
Open access Aug 2026

Prognostic Utility of the Cachexia Index in Resectable and Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Chemotherapy.

OBJECTIVES The cachexia index (CXI), integrating skeletal muscle mass, serum albumin, and the neutrophil-to-lymphocyte ratio, has been proposed as a marker of cancer-related cachexia. The objective of this study was to assess the prognostic significance of pre-treatment CXI in patients with resectable or borderline res...

Satoru Tsuruta, K. Ishido, H. Nagase et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.